SEARCH OUR PAGES

Immuno-Oncology Platform

Immuno-Oncology Platform

OSE Immunotherapeutics’ immuno-oncology platform is comprised of three programs, one of which is currently in clinical status.

OSE Immunotherapeutics is a leader in the research and development of a myeloid checkpoint inhibitor targeting the SIRPα / CD47 receptor pathway, BI 765063 (OSE-172). BI 765063 is being investigated in an ongoing Phase 1 clinical trial in advanced solid tumors under a license and collaboration agreement with Boehringer Ingelheim.

In collaboration with the CRTI (Center for Research in Transplantation and Immunology, Nantes), the Company has characterized CLEC-1 (a C-type lectin receptor) as a novel myeloid immune checkpoint and validated the first monoclonal antibody antagonists of CLEC-1 as an innovative new potential therapeutic in cancer immunotherapy.

The Company has developed a bispecific fusion protein platform (BiCKI®) built on the key backbone component anti-PD-1 (OSE-279), a novel standard of care treatment in oncology, and paired with innovative immunotherapy targets. The BiCKI® platform strives to inhibit key immune checkpoints while simultaneously delivering intratumoral cytokines with Treg modulating function and/or increasing exhausted T cell responses.

Moreover, Tedopi®, antitumor combination of neoepitopes and therapeutic vaccine, has shown positive Step-1 Phase 3 results of its Atalante 1 trial in non-small cell lung cancer with a significant increase to overall survival and good safety profile.

Platform
Target/Modality
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Partners
BI 765063 (OSE-172)
SIRPa/CD-47 Antagonist
Advanced solid tumours
Ongoing
CLEC-1
"Don't Eat Me" signal - Myeloid checkpoint
Various cancers
Ongoing
BiCKI®
T Cells + Innovative targets
Various cancers
Ongoing

Platform

  • Target Modality SIRPa/CD-47 Antagonist
  • Indication Advanced solid tumours
  • Pre-Clinical POC
  • Phase 1 Ongoing
  • Phase 2
  • Phase 3
  • Partners
  • Target Modality "Don't Eat Me" signal - Myeloid checkpoint
  • Indication Various cancers
  • Pre-Clinical POC Ongoing
  • Phase 1
  • Phase 2
  • Phase 3
  • Partners
  • Target Modality T Cells + Innovative targets
  • Indication Various cancers
  • Pre-Clinical POC Ongoing
  • Phase 1
  • Phase 2
  • Phase 3
  • Partners
  • BI 765063 (OSE-172)

    +
  • CLEC-1

    +
  • BiCKI®

    +